PTTG1 and breast carcinoma: In a combination of securin and Ki-67, the observed risk of breast cancer death was 5.8-fold (securin⩾1.5 and Ki-67⩾10% vs securin<1.5 and Ki-67<10%, P=0.004, 95% CI 1.8–18.9).